 On December 8, 2020, Greenwich LifeSciences NASDAQ: GLSI share price closed at 5.20 per share. Greenwich LifeSciences published its 5-year breast cancer data from a Phase IIb trial at the San Antonio Breast Cancer Symposium conference on December 9, which showed 0 breast cancer recurrences over 5 years of follow-up. 